Perjeta
E46091
Perjeta is a monoclonal antibody drug used in combination therapies to treat HER2-positive breast cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Perjeta canonical | 5 |
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
HER2-targeted therapy
ⓘ
antineoplastic agent ⓘ monoclonal antibody drug ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| belongsToRegimen | CLEOPATRA regimen ⓘ |
| bindsTo | HER2 dimerization domain ⓘ |
| blackBoxWarning | embryo-fetal toxicity ⓘ |
| clinicalTrial |
APHINITY trial
ⓘ
CLEOPATRA trial ⓘ |
| commonAdverseEffect |
alopecia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ rash ⓘ |
| contraindication | pregnancy ⓘ |
| EMAPositiveOpinionYear | 2013 ⓘ |
| FDAApprovalYear | 2012 ⓘ |
| hasAntibodyType | IgG1 ⓘ |
| hasATCCode | L01FD02 ⓘ |
| hasDosageForm | concentrate for solution for infusion ⓘ |
| hasDrugClass | humanized monoclonal antibody ⓘ |
| hasGenericName | pertuzumab ⓘ |
| hasManufacturer | Genentech ⓘ |
| hasMolecularType | recombinant humanized monoclonal antibody ⓘ |
| hasParentCompany | Roche ⓘ |
| hasTarget |
ERBB2
ⓘ
HER2 receptor ⓘ |
| improvesOutcome |
overall survival in HER2-positive metastatic breast cancer
ⓘ
progression-free survival in HER2-positive metastatic breast cancer ⓘ |
| indication |
HER2-positive early breast cancer
ⓘ
HER2-positive locally advanced breast cancer ⓘ HER2-positive metastatic breast cancer ⓘ |
| inhibits | HER2 dimerization ⓘ |
| isPatentProtected | true ⓘ |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
ⓘ
inhibits HER2 signaling pathways ⓘ prevents ligand-dependent HER2 heterodimerization ⓘ |
| regulatoryStatus | prescription-only medicine ⓘ |
| requiresMonitoring | left ventricular ejection fraction ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| seriousAdverseEffect |
congestive heart failure
ⓘ
left ventricular dysfunction ⓘ |
| usedInCombinationWith |
chemotherapy
ⓘ
docetaxel ⓘ Herceptin ⓘ
surface form:
trastuzumab
|
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.